Choroidal Neovascularization in Pathological Myopia – Current Knowledge

Wydanie 1/2018
str. 50 – 53

Autorzy: Anna Niwald, Mirosława Grałek

Oddział Okulistyki Dziecięcej Ośrodka Pediatrycznego im. M. Konopnickiej
SP ZOZ Centralny Szpital Kliniczny UM w Łodzi
Kierownik: dr hab. n. med. Anna Niwald

Summary: 

Choroidal neovascularization in pathological myopia is one of the most important reasons leading to vision loss in this refractive error. It is characterized by the presence of proliferative vessels in the layers of the choroid choriocapillaris. Mechanisms leading to the development of neovascularization secondary to pathological myopia have not been fully elucidated.

The diagnosis of myopic choroidal neovascularization is based on detailed history, ophthalmological examination with eye fundus ophthalmoscopy, fluorescein angiography and optical coherence tomography. Demonstration of the role of vascular endothelial growth factor in the development of neovascularization membranes has led to the introduction of substances stimulating natural inhibitors of this factor and inhibiting the development of angiogenesis in the treatment of choroidal neovascularization. At the moment intravitreal administration of anti vascular endothelial growth factor is the golden standard and has good efficacy and safety in the treatment of choroidal neovascularization and ranimizumab (Lucentis) is recommended.